MGRX_OUT_1 [2025-04-17 15:08:20 -0400] 4737 Bytes | 1227 tokens | Cum: 1227 tkns (15.34% of 8k)
==========================================================================

Alright, let’s light it up, because it's 3:08:19 PM on Thu Apr 17, 2025 -0400, and I'm charging into Mangoceuticals (MGRX), popping from 2.1000 to 2.5200. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Mangoceuticals (MGRX)
IPO: 2023-03-21 (2 Years Ago)
Market Cap: $11,112,911
Shares Outstanding: 5,170,000
Industry: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
Exchange: XNAS
Description: Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Here’s a list of headlines for Mangoceuticals:

Mar-25-25 09:00AM - Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol in the USA and Canada
Feb-20-25 07:00AM - Mangoceuticals Announces the Launch of PeachesRx - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
Feb-12-25 08:00AM - Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
Feb-06-25 07:00AM - Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
Feb-03-25 08:30AM - Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol Skincare Treatment Targeting Hyperpigmentation
Dec-19-24 05:33PM - Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dec-04-24 07:00AM - Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
Oct-31-24 08:00AM - Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Prior AI Reports for MGRX:
1. 2025-03-19 – Score: 50 – Target: 4.9000 – Highs: 4.6900 / 4.6900 / 5.01
high-volatility-and-mixed-signals-cloud-companys-outlook

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-07-12T18:11:34Z - Azz Inc. COO acquires $21.2k in company stock By Investing.com - Investing.com Australia
B2 - 2024-06-06T12:30:00Z - MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
B3 - 2024-06-04T20:00:00Z - MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
B4 - 2024-05-23T12:30:00Z - MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
B5 - 2024-05-22T10:52:00Z - Spotting Penny Stocks Before They Explode, Top Tips
B6 - 2024-05-16T20:40:00Z - MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Mangoceuticals (MGRX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

MGRX_OUT_3 [2025-04-17 15:08:21 -0400] 942 Bytes | 283 tokens | Cum: 1512 tkns (18.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T19:28:05Z - MGRX stock touches 52-week low at $1.79 amid market challenges By Investing.com...
A2 - 2025-04-04T19:27:33Z - MGRX stock touches 52-week low at $1.79 amid market challenges By Investing.com...
A3 - 2025-04-04T19:28:06Z - MGRX stock touches 52-week low at $1.79 amid market challenges By Investing.com...
A4 - 2025-04-04T19:28:05Z - MGRX stock touches 52-week low at $1.79 amid market challenges By Investing.com...
A5 - 2025-03-25T14:47:03Z - Mangoceuticals Slips 25% As It Secures Licensing And Distribution Rights For Diabetinol...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MGRX_OUT_5 [2025-04-17 15:08:22 -0400] 1181 Bytes | 304 tokens | Cum: 1818 tkns (22.73% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**MGRX stock touches 52-week low at $1.79 amid market challenges By Investing.com**Date: 2025-04-04Source: {'uri': 'uk.investing.com', 'dataType': 'news', 'title': 'Investing.com UK'}URL: https://uk.investing.com/news/company-news/mgrx-stock-touches-52week-low-at-179-amid-market-challenges-93CH-4016196In a challenging market environment, Mangoceuticals (MGRX) stock has reached a 52-week low, trading at $1.79, marking a steep 89% decline from its 52-week high of $16.80. According to InvestingPro analysis, the company maintains impressive gross profit margins of 62% despite current market challenges. The pharmaceutical company, which has been navigating through a tough year marked by increased competition and regulatory hurdles, has seen its stock price significantly retreat from previous levels. Over the past year, Mangoceuticals has experienced a substantial decline, with its stock v

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_7 [2025-04-17 15:08:23 -0400] 1181 Bytes | 259 tokens | Cum: 2079 tkns (25.99% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): alue eroding by 43%. This downturn reflects investor concerns over the company's performance and future prospects in a highly competitive sector, with InvestingPro data showing an overall "WEAK" financial health score. As Mangoceuticals strives to revitalize its strategy and pipeline, market watchers remain attentive to any signs of a turnaround that could influence the stock's trajectory. InvestingPro analysis suggests the stock is currently undervalued, with 12 additional real-time insights available for subscribers.

In other recent news, Mangoceuticals, Inc. has reported several significant developments. The company has converted its Series B Convertible Preferred Stock into common shares, resulting in the issuance of 287,467 new common shares. These conversions, completed under the exemption provided by Section 3(a)(9) of the Securities Act of 1933, are part of the company's capital

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_9 [2025-04-17 15:08:24 -0400] 1181 Bytes | 252 tokens | Cum: 2333 tkns (29.16% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): structure strategy. Additionally, the company has announced changes to its equity securities and executive compensation arrangements, including amendments to the Certificate of Designations for the Series B Convertible Preferred Stock, which reduce the conversion price to $1.50 per share.

Mangoceuticals has also entered into a consulting agreement with 6330 Investment & Consulting Gmbh, issuing 200,000 shares of restricted common stock as compensation for services in identifying strategic partners and acquisition opportunities. In a separate development, Mangoceuticals is advancing research on a water-based antiviral solution targeting avian influenza, in partnership with Vipragen Biosciences. Phase II studies are underway, with the potential to offer a non-pharmaceutical alternative to traditional vaccines.

Furthermore, the company has amended its 2022 Equity Incentive Plan, allowing

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_11 [2025-04-17 15:08:25 -0400] 651 Bytes | 148 tokens | Cum: 2483 tkns (31.04% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): for various equity-based awards and including an "evergreen" provision for automatic share increases. These updates, disclosed in an SEC filing, could influence the company's governance and ability to attract key personnel. Mangoceuticals has not provided additional commentary on the potential impact of these changes on its financial position or market performance.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_13 [2025-04-17 15:08:27 -0400] 1097 Bytes | 296 tokens | Cum: 2783 tkns (34.79% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S6 - 2025-03-25 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Master Distribution Agrmt

On March 24, 2025, Mangoceuticals, Inc. (the Company , we and us ) entered into a Master Distribution Agrmt (the MSA ), with Navy Wharf, Ltd ( Navy Wharf ). Pursuant to the MSA, the Compa...

S7 - 2025-03-20 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

Forward-looking statements

The following discussion of the Companys historical performance and financial condition should be read together with the CONS financial statements...

S8 - 2025-03-19 8-K Item 9.01 Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit

No.

Description 3.1 Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on March 28, 2024 (Filed...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MGRX_OUT_15 [2025-04-17 15:08:27 -0400] 1181 Bytes | 303 tokens | Cum: 3088 tkns (38.60% of 8k)
==========================================================================

Showing S6 (chunk 1 of 3): S6:
Item 1.01. Entry into a Material Definitive Agreement.

Master Distribution Agreement

On March 24, 2025, Mangoceuticals, Inc. (the Company , we and us ) entered into a Master Distribution Agreement (the MSA ), with Navy Wharf, Ltd ( Navy Wharf ). Pursuant to the MSA, the Company was granted the exclusive licensing rights to certain intellectual property and patent rights from Navy Wharf relating to a composition and natural formula for a nutraceutical product to manage blood glucose and Hemoglobin A1c (HbA1c) levels to be marketed and sold under the brand Diabetinol, within the United States and Canada (the Market ).

We agreed pursuant to the MSA to issue Navy Wharf 1,000,000 shares of the Companys restricted common stock (the Navy Shares ) and 10% of the net sales revenue (as described in greater detail in the MSA) we generate during the term of the MSA. The term of the MSA is

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_17 [2025-04-17 15:08:28 -0400] 1181 Bytes | 276 tokens | Cum: 3366 tkns (42.08% of 8k)
==========================================================================

Showing S6 (chunk 2 of 3): perpetual, subject to certain termination rights that either party can exercise upon a breach of the agreement by the other party, subject to certain cure rights. Additionally, in the event that we do not generate at least $1.5 million of gross sales from the sale of Diabetinol products within eighteen months from June 1, 2025, subject to a sixty day cure period and subject to our right to extend such period for up to an additional 12 months upon the payment of $5 million, our rights under the MSA in the Market become non-exclusive.

The MSA contains customary confidentiality provisions, representations and warranties of the parties, indemnification obligations, disclaimers and covenants, for an agreement of type and size of the MSA.

The description of the MSA above is not complete and is qualified in its entirety by the full text of the MSA, a copy of which is attached hereto as Exhi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_19 [2025-04-17 15:08:28 -0400] 372 Bytes | 107 tokens | Cum: 3475 tkns (43.44% of 8k)
==========================================================================

Showing S6 (chunk 3 of 3): bit 10.1 , and which is incorporated by reference into this Item 1.01 in its entirety....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MGRX_OUT_21 [2025-04-17 15:08:42 -0400] 7782 Bytes | 2099 tokens | Cum: 5576 tkns (69.70% of 8k)
==========================================================================

This is our set of metrics for Mangoceuticals.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+------------------------+
| Volume: 98,823 | Perf Month: -42.68% | Option/Short: No / Yes | Sales Y/Y TTM: -15.81% |
+---------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 171.15K | Perf Quarter: -8.67% | Short Float: 7.08% | ROE: -109.71% |
+---------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 0.69 | Index: - | Short Ratio: 1.43 | ROI: -57.67% |
+---------------------+----------------------+-------------------------+------------------------+
| RSI (14): 48.09 | Market Cap: 15.29M | Short Interest: 0.24M | Sales Surprise: - |
+---------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.43 | Shs Outstand: 6.25M | Beta: 1.89 | EPS Surprise: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA20: 6.90% | Shs Float: 3.46M | Sales Q/Q: -56.93% | P/E: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA50: -30.69% | Inst Own: 1.46% | Sales past 5Y: 2689.12% | Earnings: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA200: -30.57% | Insider Own: 44.56% | Employees: 3 | |
+---------------------+----------------------+-------------------------+------------------------+
| Perf Week: 55.90% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+---------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading by Mangoceuticals officers or majority shareholders (if available).

Inside Trans: MANGOCEUTICALS, INC. (MGRX) by MYERS KENNY (Unknown Title) on 2025-04-10
- Common Stock: 25000 shares at $0 (D) Footnote: Issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors. Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan. Exempt pursuant to Rule 16b-3.

Inside Trans: MANGOCEUTICALS, INC. (MGRX) by Isaac Antonios (President) on 2025-04-10
- Common Stock: 60000 shares at $0 (D) Footnote: Issued as a discretionary bonus in consideration for services rendered as President of the Issuer. Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan. Exempt pursuant to Rule 16b-3.

Inside Trans: MANGOCEUTICALS, INC. (MGRX) by Hamilton Alex P. (Unknown Title) on 2025-04-10
- Common Stock: 25000 shares at $0 (D) Footnote: Issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors. Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan. Exempt pursuant to Rule 16b-3.

Inside Trans: MANGOCEUTICALS, INC. (MGRX) by D'Alessio Lorraine Pamela (Unknown Title) on 2025-04-10
- Common Stock: 25000 shares at $0 (D) Footnote: Issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors. Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan. Exempt pursuant to Rule 16b-3.

Inside Trans: MANGOCEUTICALS, INC. (MGRX) by Cohen Jacob D. (Chief Executive Officer) on 2025-04-10
- Common Stock: 200000 shares at $0 (D) Footnote: Issued as a discretionary bonus in consideration for services rendered as Chief Executive Officer of the Issuer. Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan. Exempt pursuant to Rule 16b-3.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 615873, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -8707226.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.52
Average Volume: 277345.61
30-Day High: 4.75
30-Day Low: 1.565

[Detailed Financials: TTM 2024]
- Total Assets: $15,370,511.00
- Total Liabilities: $1,425,463.00
- Total Equity: $13,945,048.00
- Current Assets: $75,595.00
- Current Liabilities: $1,425,463.00

[Income Statement: TTM 2024]
- Revenue: $615,873.00
- Net Income: $-8,707,226.00
- Gross Profit: $379,964.00
- Operating Income: $-7,971,993.00
- Earnings Per Share (EPS): -4.84

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-670,508.00

[Detailed Financials: FY 2024]
- Total Assets: $15,370,511.00
- Total Liabilities: $1,425,463.00
- Total Equity: $13,945,048.00
- Current Assets: $75,595.00
- Current Liabilities: $1,425,463.00

[Income Statement: FY 2024]
- Revenue: $615,873.00
- Net Income: $-8,707,226.00
- Gross Profit: $379,964.00
- Operating Income: $-7,971,993.00
- Earnings Per Share (EPS): -4.84

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-670,508.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Mangoceuticals (MGRX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Mangoceuticals.

2) MARKET_SCORE[]
This conversation was initiated because MGRX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for MGRX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, MGRX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect MGRX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Mangoceuticals.

11) ETHICAL_RATING[]
Rate Mangoceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Mangoceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

MGRX_IN_23 [2025-04-17 15:08:42 -0400] 126 Bytes | 29 tokens | Cum: 5820 tkns (72.75% of 8k)
==========================================================================

====================================
[2025-04-17 15:08:42] # Analysis Completed
Elapsed Time: 23.01 seconds